597668 Disclosed herein are GPR 119 agonists of the general Formula (I) wherein the variables are defined in the specification, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, stereoisomers, and polymorphs. Additionally disclosed are processes for the preparation of the compounds, pharmaceutical compositions containing the compounds and to methods for treating one or both of diabetes and obesity using the compounds of the invention. The disclosed compounds are G-protein coupled receptor (GPCR) agonists that are useful for the treatment of obesity, diabetes and related metabolic disorders. Examples of the compounds include cis-5-(4-((6-(4-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-5-nitropyrimidin-4-yl)oxy)phenyl)-1,3,2-dioxathiane-2-oxide and trans-tert-butyl-4-((5-methyl-6-(4-(2-oxido-1,3,2-dioxathian-5-yl)phenoxy)pyrimidin-4-yl)oxy)piperidine-1-carboxylate.
